内镜下扩张联合黏膜下注射曲安奈德在食管良性狭窄治疗中的应用价值研究

目的探讨内镜下扩张联合黏膜下注射曲安奈德治疗食管良性狭窄的安全性及其应用价值。方法69例患者随机分为3组，分别接受单纯内镜下扩张治疗（A组）、内镜下扩张联合单次注射注射曲安奈德治疗（B组）和内镜下扩张联合多频次注射注射曲安奈德治疗（C组）。比较3组并发症发生情况、治愈率、持续症状缓解时间、再次行内镜下扩张治疗的间隔时间、内镜治疗结束后Stooler分级评分。结果术后部分患者出现胸痛及反流症状，均经对症治疗后症状改善，未出现严重出血、感染、穿孔及局部组织萎缩坏死等并发症。内镜治疗结束后3组Stooler分级评分均较术前有明显改善（P〈0．05），各组间比较差异无统计学意义（P〉0．05）。随访至52周，A组平均持续症状缓解时间及再次行内镜下扩张治疗的间隔时间分别为（14．4±3．2）周和（18．2±3．7）周，B组分别为（19．3±3．9）周和（24．6±4．2）周，C组分别为（20．2±4．2）周和（26．1±4．5）周，B组和C组均明显长于A组（P〈0．05），B、C组问差异无统计学意义（P〉0．05）；A组治愈率为29．2％（7／24），B组为27．3％（6／22），C组为43．5％（10／23），C组明显高于A组和B组（P〈0．05），A、B组间差异无统计学意义（P〉0．05）。结论食管良性狭窄采取内镜下扩张联合黏膜下注射曲安奈德治疗是安全的，多频次注射可明显提高治愈率。

Endoscopic dilatation combined with submucosal injection of triamcinolone acetonide for benign esophageal stricture

Objective To explore the safety and efficacy of endoscopic dilatation combined with submucosal injection of triamcinolone acetonide in treatment of benign esophageal stricture.Methods The patients of benign esophageal stricture proved by biopsy were randomly divided into three groups.Group A were treated by expansion only,group B were injected with triamcinolone acetonide submucosal combined with expansion,and we treated group C by another injection a week later on the basis of treatment in group B.A 12 months' follow-up was conducted,the dysphagia score,the cure rate.time to sustained symptom relief,re-expansion time interval and adverse reactions were recorded.Results Some patients experienced chest pain and regurgitation after the procedure and all improved by corresponding managements.No complications including massive bleeding,infection,perforation or local tissue atrophy were observed.The dysphagia scores in 3 groups after the procedure were all improved ( P ＜ 0.05 ),and no significant difference was noticed between 3 groups (P ＞ 0.05 ).At the end of the follow-up,the duration of dysphagia remission and the interval between 2 consecutive dilatation in Group A were 14.4 ± 3.2 weeks and 18.2 ± 3.7 weeks,respectively,which were significant shorter than those in Group B ( 19.3 ±3.9 weeks and 24.6 ±4.2 weeks,respectively) and those in Group C (20.2 ±4.2 weeks and 26.1 ±4.5 weeks,respectively),while there was no difference between Groups B and C.The cure rate in Group C (43.5％,10/23) was significantly higher than that of Group A (29.2％,7/24) or Group B (27.3％,6/22),while there was no difference between Groups A and B.Conclusion Endoscopic dilatation combined with submucosal injection of triamcinolone acetonide is safe and may improve the symptoms of dysphagia and delay the re-stenosis for patients with benign esophageal stricture,meanwhile,multi-frequency treatment may improve the cure rate.